The pharmaceutical company Double Bond Pharma has signed a research agreement with N.N. Alexandrov National Cancer Centre in Belarus for a clinical study of Temodex in glioblastoma. The study covers data from 2021–2025 and will be analyzed according to the latest WHO standard with molecular genetic criteria. Over 450 patients are expected to be included, and the project is scheduled to be completed in June 2026. No financial details are provided."This is a transformative moment for Double Bond Pharmaceutical," the company's CEO Igor Lokot says in a comment. He continues: "We are not just collecting data; we are analyzing a large patient population using the world's strictest modern diagnostic standards. This study will prove that our technology changes the trajectory of brain cancer treatment and provides the definitive validation required to bring SI-053 to the forefront of global oncology through high-level partnerships. I am convinced that these results will prove that SI-053 is a true 'game-changer' in the treatment of GBM".Double Bond Pharma further states that the study is a central pillar in the company's commercial strategy. "The results from this comprehensive five-year patient dataset are expected to significantly strengthen the company's position in ongoing negotiations with potential strategic partners," writes Double Bond Pharma.